Literature DB >> 3926880

Requirements for T cell activation by OKT3 monoclonal antibody: role of modulation of T3 molecules and interleukin 1.

R Schwab, M K Crow, C Russo, M E Weksler.   

Abstract

The requirements for activation of human peripheral blood T cells by the mitogenic monoclonal antibody OKT3 were examined. OKT3 binds to a T cell molecule, T3, associated with the T cell antigen receptor and involved in T cell activation. Activation of T cells by OKT3 requires signals provided by accessory cells and is IL 2 dependent. In the presence of accessory cells, OKT3 induces loss of T3 molecules from the cell surface, production of IL 2, expression of IL 2 receptors, and proliferation. Modulation of T3 molecules by OKT3 can be induced in the absence of accessory cells with anti-mouse IgG. These T cells, however, are not induced to express IL 2 receptors or secrete IL 2. The addition of IL 1 induces expression of IL 2 receptors, but does not induce IL 2 secretion or proliferation. Thus, peripheral blood T cells appear to have different requirements for activation compared with antigen-specific T cell clones that can be induced to produce IL 2 when stimulated with OKT3 and IL 1. Expression of IL 2 receptors does not require modulation of T3 molecules, because the binding of OKT3 to T cells in the presence of IL 1 alone is sufficient to induce IL 2 receptor expression. The results suggest that IL 2 secretion depends on cross-linking and modulation of T3 molecules, and additional, as yet undefined, accessory cell signals. The expression of IL 2 receptors and proliferation of T cells can be induced in the absence of these signals when exogenous IL 2 is provided.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3926880

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

1.  Basis for defective responses of rheumatoid arthritis synovial fluid lymphocytes to anti-CD3 (T3) antibodies.

Authors:  M Lotz; C D Tsoukas; C A Robinson; C A Dinarello; D A Carson; J H Vaughan
Journal:  J Clin Invest       Date:  1986-09       Impact factor: 14.808

Review 2.  The role of OKT3 in clinical transplantation.

Authors:  D J Norman; M R Leone
Journal:  Pediatr Nephrol       Date:  1991-01       Impact factor: 3.714

3.  Simplified long term large scale production of highly active human LAK cells for therapy.

Authors:  P Wersäll; G Masucci; P Pihlstedt; H Wigzell; H Mellstedt
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

4.  Eradication of Established Tumors by Chemically Self-Assembled Nanoring Labeled T Cells.

Authors:  Jacob R Petersburg; Jingjing Shen; Clifford M Csizmar; Katherine A Murphy; Justin Spanier; Kari Gabrielse; Thomas S Griffith; Brian Fife; Carston R Wagner
Journal:  ACS Nano       Date:  2018-06-04       Impact factor: 15.881

5.  Cell membrane is a major locus for ultraviolet B-induced alterations in accessory cells.

Authors:  J Krutmann; I U Khan; R S Wallis; F Zhang; E A Rich; J J Ellner; C A Elmets
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

6.  Plasma glutamate levels, lymphocyte reactivity and death rate in patients with bronchial carcinoma.

Authors:  H P Eck; P Drings; W Dröge
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

7.  Activation of human peripheral blood mononuclear cells by anti-T3: killing of tumor target cells coated with anti-target-anti-T3 conjugates.

Authors:  G Jung; C J Honsik; R A Reisfeld; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

8.  Synergism in the activation of human CD8 T cells by cross-linking the T-cell receptor complex with the CD8 differentiation antigen.

Authors:  F Emmrich; U Strittmatter; K Eichmann
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

Review 9.  The role of tumor necrosis factor and interleukin 1 in the immunoinflammatory response.

Authors:  J W Larrick; S L Kunkel
Journal:  Pharm Res       Date:  1988-03       Impact factor: 4.200

10.  Isotype-specific cross-linking of select human Fc gamma R isoforms triggers release of IL-6.

Authors:  A J Duits; L A Aarden; L K Ernst; P J Capel; J G van de Winkel
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.